 DUBLIN, Ireland, April 18, 2021 GLOBE NEWSWIRE -- Prothena Corporation plc NASDAQ:PRTA today presented positive results from the Phase 1 study of PRX004 as part of the Emerging Science Session at the American Academy of Neurology AAN 2021 Virtual Annual Meeting. PRX004 showed favorable results as demonstrated by slowing of neuropathy progression for all 7 evaluable patients at 9 months, including improvement in neuropathy in 3 of the 7 patients, and improved cardiac systolic function for all 7 patients. In this Phase 1 study, PRX004 was found to be generally safe and well tolerated across all dose levels. The positive results were presented by Dr. Ole Suhr, Senior Professor, Department of Public Health and Clinical Medicine, Umeå University, gastroenterologist and internist who was a principal investigator in the study and were previously highlighted by Prothena on December 9, 2020. 